4870-31-9

Basic information

• Product Name: 5-Anilinopyrimidine-2,4(1H,3H)-dione
• Synonyms: 5-Anilinopyrimidine-2,4(1H,3H)-dione;5-(phenylamino)pyrimidine-2,4(1H,3H)-dione;5-Phenylamino-1H-pyrimidine-2,4-dione
• CAS NO: 4870-31-9
• Molecular Formula: C₁₀H₉N₃O₂
• Molecular Weight: 203.2
• Mol File: 4870-31-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.375g/cm³
• Refractive Index: 1.655
• CAS DataBase Reference: 5-Anilinopyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Anilinopyrimidine-2,4(1H,3H)-dione(4870-31-9)
• EPA Substance Registry System: 5-Anilinopyrimidine-2,4(1H,3H)-dione(4870-31-9)

Safety Data

• Hazardous Substances Data: 4870-31-9(Hazardous Substances Data)

Usage

Description

5-Anilinopyrimidine-2,4(1H,3H)-dione, also known as ANP, is a chemical compound with potential anticancer and antiproliferative properties. It is known for its ability to inhibit the proliferation of cancer cells by interfering with their DNA repair mechanisms. ANP also inhibits the enzyme poly (ADP-ribose) polymerase (PARP), which plays a crucial role in DNA repair and has been targeted for cancer therapy. 5-Anilinopyrimidine-2,4(1H,3H)-dione has shown promise in combination with other chemotherapeutic agents to enhance their effectiveness against cancer cells. Ongoing research into the therapeutic potential of ANP may offer new approaches to treating various types of cancer.

Uses

Used in Oncology:
5-Anilinopyrimidine-2,4(1H,3H)-dione is used as an anticancer agent for its potential to inhibit the proliferation of cancer cells. It targets the DNA repair mechanisms of these cells, thereby disrupting their ability to repair damage and promoting cell death.
Used in Combination Therapy:
In the field of oncology, 5-Anilinopyrimidine-2,4(1H,3H)-dione is used as a component in combination therapy to enhance the effectiveness of other chemotherapeutic agents. Its ability to inhibit PARP makes it a valuable addition to treatment regimens, potentially increasing the sensitivity of cancer cells to other treatments and improving overall therapeutic outcomes.
Used in Drug Development:
5-Anilinopyrimidine-2,4(1H,3H)-dione is utilized in drug development as a compound with potential for the creation of new anticancer drugs. Its unique mechanism of action and synergistic effects with existing therapies make it a promising candidate for further research and development in the pharmaceutical industry.
Used in Research:
In the scientific research field, 5-Anilinopyrimidine-2,4(1H,3H)-dione is used as a subject of study to explore its potential applications in cancer treatment. Ongoing research aims to understand its mechanisms of action, optimize its use in combination therapies, and identify the types of cancer it may be most effective against.
Used in Preclinical Models:
5-Anilinopyrimidine-2,4(1H,3H)-dione is employed in preclinical models to test its efficacy and safety before moving on to clinical trials. These models help researchers evaluate the compound's potential as a standalone treatment or in combination with other agents, providing valuable data to inform future cancer treatment strategies.

InChI:InChI=1/C10H9N3O2/c14-9-8(6-11-10(15)13-9)12-7-4-2-1-3-5-7/h1-6,12H,(H2,11,13,14,15)

Upstream product

• 51-20-7 5-bromouracil 
• 62-53-3 aniline 
• 181035-64-3 1-benzyloxymethyl-5-bromouracil 

Downstream Products

• 220959-91-1 2,4-bis(trimethylsilyloxy)-5-phenylaminopyrimidine 
• 220959-90-0 5-(4-bromophenylamino)uracil 
• 4882-60-4 (2,4-dichloro-pyrimidin-5-yl)-phenyl-amine 
• 1401466-21-4 N-(3-(2-chloro-5-(phenylamino)pyrimidin-4-yl)phenyl)acrylamide 
• 1401466-22-5 N-(3-(2-((4-morpholinophenyl)amino)-5-(phenylamino)pyrimidin-4-yl)phenyl)acrylamide 

Relevant articles and documents

Synthesis of acyclic nucleoside phosphonates targeting flavin-dependent thymidylate synthase in Mycobacterium tuberculosis

Flavin-Dependent Thymidylate Synthase (FDTS) encoded by ThyX gene was discovered as a new class of thymidylate synthase involved in the de novo synthesis of dTMP named only in 30 % of human pathogenic bacteria. This target was pursed for the development of new antibacterial agents against multiresistant pathogens. We have developed a new class of ANPs based on the mimic of two natural's cofactors (dUMP and FAD) as inhibitors against Mycobacterium tuberculosis ThyX. Several synthetic efforts were performed to optimize regioselective N1-alkylation, cross-coupling metathesis and Sonogashira cross-coupling. Compound 19c showed a poor 31.8% inhibitory effect on ThyX at 200 μM.

Synthesis of substituted uracils by the reactions of halouracils with selenium, sulfur, oxygen and nitrogen nucleophiles under focused microwave irradiation

Under microwave irradiation, the nucleophilic substitution reactions of halouracils with selenium, sulfur, oxygen and nitrogen nucleophiles was complete within several minutes with yields up to 99%. The method using microwave irradiation is superior to th

INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS

The present invention provides compounds of formula (I): These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.